Emerging biological therapies for systemic lupus erythematosus

OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE

(2014) R. Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0003 A Randomized Controlled Study of Laquinimod in Active Lupus Nephritis Patients in Combination with Standard of Care

(2014) D. Jayne et al.   ANNALS OF THE RHEUMATIC DISEASES

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids

(2013) Marie B Condon et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial

(2013) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

(2013) Michelle A. Petri et al.   ARTHRITIS AND RHEUMATISM

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

(2013) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

(2013) E. A. Rossi et al.   BLOOD

Targeting the complement system in systemic lupus erythematosus and other diseases

(2013) Maria-Louise Barilla-LaBarca et al.   CLINICAL IMMUNOLOGY

Bortezomib for the treatment of previously untreated multiple myeloma

(2013) Alessandra Romano et al.   Immunotherapy

Overview of lupus nephritis management guidelines and perspective from Asia

(2013) Chi Chiu Mok et al.   International Journal of Rheumatic Diseases

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

(2013) E. M. Ginzler et al.   JOURNAL OF RHEUMATOLOGY

Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy

(2013) J Mosak et al.   LUPUS

Targeted therapies in systemic lupus erythematosus

(2013) P Grech et al.   LUPUS

Epratuzumab for Systemic Lupus Erythematosus

(2013) DJ Wallace et al.   LUPUS

Belimumab for Systemic Lupus Erythematosus

(2013) Bevra Hannahs Hahn   NEW ENGLAND JOURNAL OF MEDICINE

The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus

(2013) Zev Sthoeger et al.   PLoS One

Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus

(2013) L. Quartuccio et al.   RHEUMATOLOGY

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

(2013) Daniel J. Wallace et al.   RHEUMATOLOGY

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

(2013) Venkat Reddy et al.   ARTHRITIS RESEARCH & THERAPY

Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity

(2012) Keishi Fujio et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

(2012) Robert Zimmer et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter

(2012) Sarah Gheuens et al.   Annual Review of Pathology-Mechanisms of Disease

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

(2012) Jacqueline M. McBride et al.   ARTHRITIS AND RHEUMATISM

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

(2012) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions

(2012) David Wofsy et al.   ARTHRITIS AND RHEUMATISM

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

(2012) Bernard R. Lauwerys et al.   ARTHRITIS AND RHEUMATISM

Type I IFN system in the development and manifestations of SLE

(2012) Keith B. Elkon et al.   CURRENT OPINION IN RHEUMATOLOGY

Abatacept for systemic lupus erythematosus: the outlook

(2012) Chi Chiu Mok   EXPERT OPINION ON BIOLOGICAL THERAPY

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus

(2012) Kirsten Fairfax et al.   IUBMB LIFE

Peptide-based approaches to treat lupus and other autoimmune diseases

(2012) Nicolas Schall et al.   JOURNAL OF AUTOIMMUNITY

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial

(2012) W. WINN CHATHAM et al.   JOURNAL OF RHEUMATOLOGY

Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study

(2012) A Fernández-Nebro et al.   LUPUS

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

(2012) DJ Wallace et al.   LUPUS

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

(2012) MA Dooley et al.   LUPUS

Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis

(2012) Marc Weidenbusch et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months

(2012) Z. Touma et al.   RHEUMATOLOGY

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

(2012) Ellen M Ginzler et al.   ARTHRITIS RESEARCH & THERAPY

Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis

(2012) Wolfgang Brück et al.   Expert Review of Clinical Pharmacology

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China

(2011) C. C. Mok et al.   ARTHRITIS AND RHEUMATISM

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

(2011) R. F. van Vollenhoven et al.   ARTHRITIS AND RHEUMATISM

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

(2011) H. Travis Ichikawa et al.   ARTHRITIS AND RHEUMATISM

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

(2011) Cándido Díaz-Lagares et al.   AUTOIMMUNITY REVIEWS

PML and rheumatology: The contribution of disease and drugs

(2011) E. S. MOLLOY   CLEVELAND CLINIC JOURNAL OF MEDICINE

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside

(2011) William Stohl et al.   CURRENT OPINION IN RHEUMATOLOGY

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

(2011) Matthew M. Seavey et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials

(2011) Z. TOUMA et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy

(2011) D. Roccatello et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma

(2010) K. Frohlich et al.   ANNALS OF THE RHEUMATIC DISEASES

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

(2010) J. T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Update on emerging drug therapies for systemic lupus erythematosus

(2010) Chi Chiu Mok   EXPERT OPINION ON EMERGING DRUGS

Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells

(2010) Clemens Scheinecker et al.   JOURNAL OF AUTOIMMUNITY

Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese

(2010) CC Mok   LUPUS

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

(2010) F. Catapano et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)

(2010) William Stohl   ARTHRITIS RESEARCH & THERAPY

The role of dendritic cells in the pathogenesis of systemic lupus erythematosus

(2010) Justin H Fransen et al.   ARTHRITIS RESEARCH & THERAPY

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study

(2009) Jason W. Bauer et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

(2009) Annett M. Jacobi et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome

(2009) C. Melander et al.   Clinical Journal of the American Society of Nephrology

Genetics of systemic lupus erythematosus and Sjögrenʼs syndrome

(2009) R Hal Scofield   CURRENT OPINION IN RHEUMATOLOGY

Abetimus sodium: a medication for the prevention of lupus nephritis flares

(2009) Diane M Horowitz et al.   EXPERT OPINION ON PHARMACOTHERAPY

The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients

(2009) Zev M. Sthoeger et al.   HUMAN IMMUNOLOGY

CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn-/- Mice

(2009) S. A. Oracki et al.   JOURNAL OF IMMUNOLOGY

Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases

(2009) M Ramos-Casals et al.   LUPUS

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

(2009) John N. Boletis et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

(2009) E. K. Li et al.   RHEUMATOLOGY

The Pathophysiologic Role of Monocytes and Macrophages in Systemic Lupus Erythematosus: A Reappraisal

(2009) Christina G. Katsiari et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

(2008) D Albert et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial

(2008) Sylviane Muller et al.   ARTHRITIS AND RHEUMATISM

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

(2008) Mario H. Cardiel et al.   ARTHRITIS AND RHEUMATISM

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE

Proteasome inhibition: a new therapeutic option in lupus nephritis?

(2008) J. van der Vlag et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2‐year prospective study

(2008) C. C. Mok et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY

Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus

(2007) M Nikpour et al.   ANNALS OF THE RHEUMATIC DISEASES